Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.

Ioannis A Vathiotis Myrto K MoutafiPrajan DivakarThazin Nwe AungTao QingAileen FernandezVesal Yaghoobi Sarra El-AbedYingbo WangSebastien Guillaume Paolo G Nuciforo Jens HuoberSerena Di CosimoSung-Bae Kim Nadia Harbeck Henry L GómezSaba ShafiKonstantinos N SyrigosGeorge FountzilasChristos Sotiriou Lajos PusztaiSarah WarrenDavid L Rimm

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

This work identifies α-SMA as a novel, easy-to-implement biomarker of resistance to trastuzumab that may be valuable in settings where trastuzumab is combined with other therapies.

Keyphrases

smooth muscle
positive breast cancer
epidermal growth factor receptor
early stage
metastatic breast cancer
poor prognosis
tyrosine kinase
genome wide
sentinel lymph node
radiation therapy
binding protein
squamous cell carcinoma
gene expression
long non coding rna
dna methylation